Navigation Links
Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer
Date:3/18/2009

PRINCETON, N.J., March 18 /PRNewswire/ -- Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, announced that it completed enrollment in its pivotal Phase III study of nonpegylated liposomal doxorubicin (Myocet(TM)) in metastatic HER-2-overexpressing breast cancer. This is a pivotal Phase III trial of Sopherion's lead product in combination with the current standard of care, paclitaxel (Taxol) and trastuzumab (Herceptin(R)), vs. paclitaxel and trastuzumab alone. Progression-free survival (PFS) is the primary efficacy endpoint, with careful monitoring for cardiac safety.

Dr. Jose Baselga, Chairman & Professor of Medicine, Vall d'Hebron Institute of Oncology (V.H.I.O.), Vall d'Hebron University Hospital in Barcelona, Spain, and principal investigator for the trial, said, "I am pleased to see that the recruitment phase of the Phase III trial has now been completed. This registration trial is based on our recently published, Roche-supported study conducted by the Spanish Breast Cancer Cooperative Group (SOLTI). Results showed that Myocet, in combination with trastuzumab and paclitaxel treatment, yielded an unusually high clinical response rate and time to progression in patients with HER-2 overexpressing breast cancer; the 3 drug combination was well tolerated with no cases of treatment-related symptomatic congestive heart failure. "

Phase III Study Design

The study is a global, randomized, multicenter pivotal Phase III study in 363 patients who have metastatic HER-2-overexpressing breast cancer. Eligibility criteria included no prior chemotherapy for metastatic disease, nor any trastuzumab, anthracyclines or taxanes within the previous 12 months. Eligible patients were randomized to receive either Myocet, paclitaxel and trastuzumab, or paclitaxel and trastuzumab alone in a 1:1 randomiza
'/>"/>

SOURCE Sopherion Therapeutics, LLC
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Sopherion Therapeutics Secures $55 Million in Series C Funding
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. FDA Accepts IND for Arno Therapeutics Pan-DAC / Akt Inhibitor, AR-42
4. Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA
5. United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso)
6. Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
7. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
8. Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
9. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
10. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 16
11. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... , NEW YORK, Dec. 1 Repo...report is available in its catalogue: ,, Emerg...ket dynamics and the changing healthcare and regul...com/p0165658/Emerging-Clinical-Trial-Locations---E...lthcare-and-regulatory-environment.html ,, Ove...
(Date:12/1/2009)... , SARASOTA, Fla., Dec. 1 Ex... Osprey Biotechnics Inc. of Sarasota has appointed...ibutor. ,, Lake is located near Birmingham, En...l bacteria which serve the agricultural, waste wat...ed to be hungry and to open drain fields, and clea...
(Date:12/1/2009)... Congruent Software agrees to ...ding project accounting clients) to Synergy Busine... Seattle, WA (PRWEB) December 1,...y it has acquired the Microsoft Dynamics SL practi...technology provider. The move was necessary due to...
(Date:12/1/2009)... , HARBIN, China, Dec. 1 /PRNewswi...("China Sky One Medical" or "the Company") (Nasdaq...al company developing and producing,over-the-count..., today,announced that the Company has engaged Gua...ce Company ("MDK") to serve as its exclusive sales...
Breaking Biology Technology:Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 2Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 3Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 4Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 5Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 6Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 7Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 8Synergy Business Solutions Acquires the Microsoft Dynamics SL Practice of Congruent Software, Inc. 2Synergy Business Solutions Acquires the Microsoft Dynamics SL Practice of Congruent Software, Inc. 3China Sky One Medical, Inc. Signs Distribution Agreement with MDK for the Sale of Two Diagnostic Kits in Southeast Asia 2China Sky One Medical, Inc. Signs Distribution Agreement with MDK for the Sale of Two Diagnostic Kits in Southeast Asia 3
... have discovered that certain organicor carbon-bas...certain circumstances and, in turn, conduct electr...dition of Science, the finding is a breakthrough i...rategy for designing electronic materials, includi...ors that have long been considered the key to smal...
...oalition (NTOCC) Advisory Task Force today authori...lping healthcare professionals and,organizations a... from one,level of care to another. The tools repr...ration between 29 industry stakeholders who joined... with transitions of care.,In addition, NTOCC is a...
...to Develop Therapies for Critica... Cleveland Clinic and Rutgers,University are leadi...op,innovative medical therapies for the treatment ...receive more than $10 million from a total of $42....titute called the Armed,Forces Institute of Regene...
Other Biology Technology:Breakthrough in nanotechnology by uncovering conductive property of carbon-based molecules 2Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care 2Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care 3Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care 4Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care 5Cleveland Clinic and Rutgers to Lead Newly Formed Institute for War Wounded 2Cleveland Clinic and Rutgers to Lead Newly Formed Institute for War Wounded 3
(Date:12/1/2009)...n July the scientists, one from the United States,...n Brutus, the leader of his wolf pack, on remote E...e. Their goal to finally find out what these "Nor...r in one of the harshest areas of the world., "W...," said David Mech, a renowned U.S. Geological Sur...
(Date:12/1/2009)... , NEW YORK, Dec. 1 iQor, ...(BPO) services, was included in the 2009 InfoWorl...iometric-enabled ERP system, TeQ21. This was the f... be recognized among this prestigious list of comp...or. "TeQ21 is completely transforming the way we d...
(Date:12/1/2009)..., RICHLAND, Wash. -- Time-lapsed video of individ...n event in the life of a cell: a protein that cycl... results give researchers a more complete view of ...s to grow, events that go awry in cancer and are t...which helps cells respond to growth factors, trave...
Breaking Biology News(10 mins):North Pole wolf emails locations to researchers 2North Pole wolf emails locations to researchers 3iQor Named to InfoWorld 100 List of Top IT Projects of 2009 2ERK's got rhythm: Protein that controls cell growth found to cycle in and out of cell nucleus 2ERK's got rhythm: Protein that controls cell growth found to cycle in and out of cell nucleus 3ERK's got rhythm: Protein that controls cell growth found to cycle in and out of cell nucleus 4Doctor Diabetic Supply Inc Acquires Diabetes Source Rx 49107 1Doctor Diabetic Supply Inc Acquires Diabetes Source Rx 49107 2Noldus Announces The Observer XT 9 0 49102 1Noldus Announces The Observer XT 9 0 49102 2FDA Issues Warning for Over the Counter Cold Remedy 49098 1FDA Issues Warning for Over the Counter Cold Remedy 49098 2FDA Issues Warning for Over the Counter Cold Remedy 49098 3
...MADISON Times are tough for wildlife living at th...lic of the Congo. Armies are reportedly encamped i...golese side, while displaced herders and their cat...And yet, the profusion of prey in the region could...the emblematic African lion, according to new rese...
..., DAVIS--Researchers at the University of Califor...educes heart enlargement, one of the most common c...ccurs when the heart can,t pump enough blood throu...ited States. The condition contributes to 300,000 ...ries of cardiologist and cell biologist Nipavan Ch...
..., A recent study by researchers at the University ...und that scientists, knowledge of the evolution of...y biologists use two ways to study the evolution o... radioactive dating techniques to put fossils in c...ks in which they are found (stratigraphy); secondl...
Other Biology News:Research uncovers surprising lion stronghold in war-torn central Africa 2Research uncovers surprising lion stronghold in war-torn central Africa 3UC Davis research shows that newly discovered drug reduces heart enlargement 2Dinosaur fossils fit perfectly into the evolutionary tree of life 2
Normal Donor Donkey Serum - 100mL from GeneTex
Goat Anti-Human PPP2R5B Polyclonal Antibody, Unconjugated from AbD Serotec
Dog Serum Non-Sterile Trace-Hemolyzed from Pel-Freez Biologicals
acridine orange 10-nonyl bromide (nonyl acridine orange) from Molecular Probes (Invitrogen)
Biology Products: